Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-16-676729
Filing Date
2016-08-09
Accepted
2016-08-09 16:03:06
Documents
56
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d211463d10q.htm 10-Q 374709
2 EX-31.1 d211463dex311.htm EX-31.1 8216
3 EX-31.2 d211463dex312.htm EX-31.2 8201
4 EX-32.1 d211463dex321.htm EX-32.1 4255
  Complete submission text file 0001193125-16-676729.txt   3023064

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT cbay-20160630.xml EX-101.INS 609289
6 XBRL TAXONOMY EXTENSION SCHEMA cbay-20160630.xsd EX-101.SCH 38615
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cbay-20160630_cal.xml EX-101.CAL 52491
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cbay-20160630_def.xml EX-101.DEF 113472
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE cbay-20160630_lab.xml EX-101.LAB 310460
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cbay-20160630_pre.xml EX-101.PRE 211774
Mailing Address 7999 GATEWAY BLVD SUITE 130 NEWARK CA 94560
Business Address 7999 GATEWAY BLVD SUITE 130 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Filer) CIK: 0001042074 (see all company filings)

EIN.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36500 | Film No.: 161817820
SIC: 2834 Pharmaceutical Preparations